| Literature DB >> 29185448 |
Séverine Remy1,2,3, Vanessa Chenouard4,5,6, Laurent Tesson4,5,6, Claire Usal4,5,6, Séverine Ménoret4,5,6, Lucas Brusselle4,5,6, Jean-Marie Heslan4,5,6,7, Tuan Huan Nguyen4,5,7, Jeremy Bellien8, Jean Merot9, Anne De Cian10, Carine Giovannangeli10, Jean-Paul Concordet10, Ignacio Anegon11,12,13.
Abstract
The generation of gene-edited animals using the CRISPRs/Cas9 system is based on microinjection into zygotes which is inefficient, time consuming and demands high technical skills. We report the optimization of an electroporation method for intact rat zygotes using sgRNAs and Cas9 protein in combination or not with ssODNs (~100 nt). This resulted in high frequency of knockouts, between 15 and 50% of analyzed animals. Importantly, using ssODNs as donor template resulted in precise knock-in mutations in 25-100% of analyzed animals, comparable to microinjection. Electroporation of long ssDNA or dsDNA donors successfully used in microinjection in the past did not allow generation of genome-edited animals despite dsDNA visualization within zygotes. Thus, simultaneous electroporation of a large number of intact rat zygotes is a rapid, simple, and efficient method for the generation of a variety of genome-edited rats.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29185448 PMCID: PMC5707420 DOI: 10.1038/s41598-017-16328-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1CRISPR/Cas9 mediated HDR strategies using ssODN. (a) Schematic illustration of the target sequences + PAM sequence (in bold) into rat Ephx2 (upper left) and FlnA (upper right) loci and the respective ssODN (100 nt and 119 nt in length) designed to insert a XbaI or an AatII recognition site (underlined in red, small letters mutations introduced into the genome). These mutations prevent further cleavage of the Ephx2 mutated gene by CRISPR/cas9 and additional mutations were introduced into FlnA ssODNs to prevent cleavage of this template (indicated by stars). The position of each primer is indicated on the schematic rat Ephx2 and FlnA loci. (b) (upper left) Ephx2 PCR analysis of a representative panel of 7 rats from the group electroporated with Cas9 (3 µM)/sgRNA Ephx2 (150 ng/µl)/ssODN (150 ng/µl) using the following poring pulse conditions: 300 V/0.5 ms (#a,#c) and 300 V/2.5 ms (#b,#d,#e,#f,#g). Capillary gels show the rEphx2 PCR products of the 670 bp expected size and of 373 bp and 297 bp after XbaI digestion. All animals with the exception of one (#a) showed XbaI digestion and two animals (#b and #g) showed disappearance of the 670 bp PCR product suggesting homozygous KI insertion. (lower left) Sequencing of the subcloned PCR products from positive animals. Deletions are indicated by “Δ”, insertions by “Ins” and knock-in events are indicated by “KI”. XbaI recognition sites are underlined in inserted alleles. In four animals (#c,#d,#e,#f) both NHEJ and knock-in events were observed. Two animals are homozygous KI (#b,#g) and one is WT (#a). *Sequence analyses of clones from animals #c, #d and #e are detailed in Table S2. (upper right) FlnA PCR analysis of the 2 representative rats from the group electroporated with Cas9 (3 µM) /sgRNA FlnA (150 ng/µl) /ssODN (150 ng/µl) using the poring pulse condition 300 V/0.5 ms. Capillary gels show the FlnA PCR products of the 512 bp expected size and of 308 bp and 204 bp after AatII digestion. One of both animals (i) showed AatII digestion suggesting a knock-in event. (lower right) Sequencing of the PCR products from the positive animal. Knock-in event is indicated by “KI”. AatII recognition site is underlined in inserted alleles.
CRISPR/Cas9 protein-mediated genome editing with ssODN matrix.
| Target locus | Cas9 (µM)/sgRNA (ng/µl)/ssODN (ng/µl) | Poring pulse conditions: voltage/pulse width | No. of viable embryos/No. of total embryos (%)a | Stage of analysis | No. of embryos or pups analyzed/No. of transferred (%)b | No. of NHEJ+ (%)c | No. of KI+ (%) c | No. of NHEJ+ KI+ (%)c | No. of embryos/pups with 3 or more alleles (%)c |
|---|---|---|---|---|---|---|---|---|---|
|
| 50*/10/15 | Microinjection | 293/373 (79) | pups | 82/250 (33) | 17 (21) | 12 (15) | 8 (9.8) | 9 (11) |
| 3/150/150 | 300 V/0.5 ms | 85/85 (100) | E14 | 20/63 (32) | 10 (50) | 1 (5)# | 1 (5)# | 4 (20) | |
| 300 V/2.5 ms | 97/134 (72) | E14 | 20/87 (23) | 12 (60) | 5 (25)# | 3 (15)# | 2 (10) | ||
| 6/200/200 | 250 V/0.5 ms | 62/70 (89) | E14 | 5/48 (10) | 0 (0) | 1 (20) | 0 (0) | 0 (0) | |
| 250 V/2.5 ms | 36/54 (67) | E14 | 1/36 (3) | 0 (0) | 0 (0) | 0 (0) | / | ||
| 300 V/0.5 ms | 31/36 (86) | E14 | 3/31 (10) | 1 (33) | 0 (0) | 0 (0) | 0 (0) | ||
| 300 V/2.5 ms | 14/47 (30) | E14 | 0/14 (0) | / | / | / | / | ||
|
| 3/100/20 | Microinjection | 121/144 (84) | pups | 21/111 (19) | 3 (14) | 2 (9.6) | 1 (4.8) | 2 (9.5) |
| 3/150/150 | 300 V/0.5 ms | 100/103 (97) | pups | 12/100 (12) | 1 (8) | 1 (8)# | 0 (0) | 0 (0) | |
| 300 V/2.5 ms | 70/119 (59) | pups | 1†/100 (1.4) | 1† (100) | 0 (0) | 0 (0) | 0 (0) |
*Cas9 mRNA (ng/µl). aCalculated 1 h after electroporation. bCalculated from the number of transferred eggs. cCalculated from the number of analyzed embryos or pups. †Stillborn pup. #Sequences detailed in Fig. 1.
Figure 2CRISPR/Cas9 mediated HDR strategies using long dsDNA template. (a) Schematic representation of the rat Rosa26 locus with the site of CRISPRs/Cas9 cleavage (arrow). (b) The targeting vectors containing a CAG-GFP expression cassette (3108 bp) and two homology arms (5′HA 813 bp and 3′ HA 783 bp) contiguous to the cleavage point. These targeting vectors were either in a linear (excised fragment) or supercoiled form. (c) Confocal microscopy images were captured the day after electroporation of rhodamine-labeled linear dsDNA (the same as in b) into intact rat zygotes using a 300 v poring pulse and a pulse width adjusted to 0.5 or 2.5 ms and then cultured overnight. (upper) Embryo electroporated with pulse width of 2.5 ms without incorporated DNA. (middle) Embryo electroporated with pulse width of 0.5 ms. (lower) Embryo electroporated with pulse width of 2.5 ms. ZP, zona pellucida; Cyt, cytoplasm. Pronuclei are indicated by dotted circles. (d) The same targeting vector as in (b) with a DNA targeting sequence (DTS) in a linear form or in a supercoiled form and in this case including Rosa26 targeted sequences (RTS) to be linearized in cellulo by the sgRNA. (e) A linear dsDNA containing the same GFP expression cassette as in (b) but without Rosa26 homology arms. Also depicted, the ssODNs containing 50 bp homologies with Rosa26 sequences at each extremity (in black) and 50 bp homologies with each extremity of the expression cassette (in red).
CRISPR/Cas9 protein-mediated genome editing of Rosa26 locus with a long dsDNA matrix.
| Cas9 (µM)/sgRNA (ng/µl)/dsDNA (ng/µl) | +ssODN Rosa (ng/µl) | Poring pulse conditions: voltage pulse/width | No. of viable embryos/No. of total embryos (%)a | Stage of analysis | No. of embryos analyzed/No. of transferred (%)b | No. of NHEJ+ (%)c | No. of KI+ (%) c |
|---|---|---|---|---|---|---|---|
| 3/100/2* | / | Microinjection | 121/160 (76) | E14 | 57/117 (49) | 13 (23) | 2 (3.5) |
| 3/150/100* | / | 300 V/0.5 ms | 32/37 (86) | E14 | 6/32 (19) | 1 (17) | 0 (0) |
| 300 V/2.5 ms | 28/47 (60) | E14 | 5/28 (18) | 0 (0) | 0 (0) | ||
| 3/150/100** | / | 300 V/0.5 ms | 31/31 (100) | E14 | 19/31 (61) | 18 (95) | 0 (0) |
| 300 V/2.5 ms | 24/27 (89) | E14 | 4/24 (17) | 4 (100) | 0 (0) | ||
| 3/150/100*** | / | 300 V/0.5 ms | 48/56 (86) | E14 | 5/48 (10) | 2 (40) | 0 (0) |
| 300 V/2.5 ms | 31/62 (50) | E14 | 1/31 (3.2) | 0 (0) | 0 (0) | ||
| 3/150/100**** | / | 300 V/0.5 ms | 46/48 (96) | E14 | 14/37 (38) | 3 (21) | 0 (0) |
| 300 V/2.5 ms | 37/50 (74) | E14 | 2/37 (5.4) | 2 (100) | 0 (0) | ||
| 3/150/100* | 300 | 300 V/0.5 ms | 30/31 (97) | E14 | 10/30 (33.3) | 6 (60) | 0 (0) |
| 300 V/2.5 ms | 59/83 (71) | E14 | 10/51 (20) | 4 (40) | 0 (0) |
*linear excised. **supercoiled. ***linear excised fragment + DTS sequence. ****Supercoiled + DTS sequence + sgRosa. aCalculated 1 h after electroporation. bCalculated from the number of transferred eggs. cCalculated from the number of analyzed embryos or pups.
Figure 3CRISPR/Cas9 mediated HDR strategies using long ssDNA templates. (a) Schematic illustration of the rat Ephx2 locus with the site of CRISPRs/Cas9 cleavage (arrow) and DNA repair templates containing a DNA sequence detailed in (b) and two homology arms (5′HA and 3′ HA) contiguous to the cleavage point. (b) Strategies tested into Ephx2 locus include a 500 nt (upper diagram) or a 1978 nt long ssDNA lower diagram), containing respectively a partial GFP sequence (387 nt) or a RSV-GFP-polyA expression cassette (1865 nt) and two homology arms (42 nt in 5′ and 52 nt in 3′). (c) Schematic illustration of the rat Rosa26 locus with the site of CRISPRs/Cas9 action (arrow) and DNA repair templates containing a DNA sequence detailed in (d) and two homology arms (5′HA and 3′ HA) contiguous to the cleavage point. (d) Strategy tested into Rosa26 locus includes a 4700 nt long ssDNA, containing a CAG-GFP expression cassette (3108 nt) and two homology arms (5′HA 813 nt and 3′ HA 783 nt).
CRISPR/Cas9 protein-mediated genome editing with a long ssDNA matrix.
| Target locus | Size of ssDNA (nt) | Cas9 (µM)/sgRNA (ng/µl)/ssDNA (ng/µl) | Poring pulse conditions: voltage/pulse width | No. of viable embryos/No. of total embryos (%)a | Stage of analysis | No. of embryos analyzed/No. of transferred (%)b | No. of NHEJ+ (%)c | No. of KI+ (%) c |
|---|---|---|---|---|---|---|---|---|
|
| 500 | 3/150/20 | 300 V/0.5 ms | 132/140 (94) | E14 | 10/91 (11) | 0 (0) | 0 (0) |
| 300 V/2.5 ms | 88/160 (55) | E14 | 18/46 (39) | 2 (11) | 0 (0) | |||
| 1978 | 3/150/20 | 300 V/0.5 ms | 68/70 (97) | E14 | 29/68 (43) | 5 (17) | 0 (0) | |
| 300 V/2.5 ms | 65/84 (77) | E14 | 2/36 (5.6) | 1 (50) | 0 (0) | |||
|
| 4700 | 3/150/20 | 300 V/0.5 ms | 35/37 (97) | E14 | 6/35 (17) | 3(50) | 0 (0) |
| 300 V/2.5 ms | 25/39 (64) | E14 | 0/25 (0) | 0 (0) | 0 (0) | |||
| 3/150/40 | 300 V/0.5 ms | 29/30 (97) | E14 | 4/29 (14) | 1 (25) | 0 (0) | ||
| 300 V/2.5 ms | 15/33 (46) | E14 | 0/15 (0) | 0 (0) | 0 (0) | |||
| 3/150/60 | 300 V/0.5 ms | 35/53 (66) | E14 | 3/30 (10) | 1 (33) | 0(0) | ||
| 300 V/2.5 ms | 30/34 (88) | E14 | 10/30 (33) | 2 (20) | 0(0) |
aCalculated 1 h after electroporation. bCalculated from the number of transferred eggs. cCalculated from the number of analyzed embryos or pups.
Figure 4CRISPR/Cas9 mediated HDR strategies using OVL ssODN templates. (a) Schematic illustration of the rat Ephx2 locus with the site of CRISPRs/Cas9 cleavage (arrow) and the 3 overlapping ssODN (OVL1-OVL2-OVL3) of concordant polarity used as DNA repair template. The 3 overlapping ssODN are designed to generate a 228 nt insert at the rEphx2 locus. Each ssODN had a 120 nt length. The two external ssODN (OVL1 and OVL3) had a 33 nt overlap with the internal ssODN (OVL2) and a 33 nt HA corresponding to the left or the right side of the DSB. (b) Schematic illustration of the rat Ephx2 locus with the site of CRISPRs/Cas9 action (arrow) and the 3 overlapping ssODN (OVL1-OVL2-OVL3) of discordant polarity used as DNA repair template. The 3 overlapping ssODN are designed to generate a 228 nt insert at the rEphx2 locus. Each ssODN had a 120 nt length. The two external ssODN (OVL1 and OVL3) had a 33 nt overlap with the internal ssODN (OVL2) and a 33 nt HA corresponding to the left or the right side of the DSB. (c) Sequencing of the subcloned PCR products from embryos for which partial OVL ssODN insertion have been observed. 5′HA and 3′HA are underlined. Deletions are indicated in bold by “Δ”, insertions by “Ins” and in bold uppercase. OVL1, 2 or 3 insertions are indicated respectively in green, blue and red.
CRISPR/Cas9 protein-mediated genome editing with overlapping ssDNA matrix.
| Target locus | Repair template | Cas9 (µM)/sgRNA (ng/µl)/ssDNA (ng/µl) | Poring pulse conditions: voltage pulse width | No. of viable embryos/No. of total embryos (%)a | Stage of analysis | No. of embryos analyzed/No. of transferred (%)b | No. of NHEJ+ (%)c | No. of KI+ (%) c | KI+ embryo IDd |
|---|---|---|---|---|---|---|---|---|---|
|
| OVL 1.5p-2-3.3p | 3/150/3 × 20 | Microinjection | 78/98 (80) | E14 | 18/54 (33) | 2 (11) | 1* (5.6) | M.OVL-E18 |
| 3/150/3 × 50 | 250 V/0.5 ms | 30/30 (100) | E14 | 4/30 (13) | 2 (50) | 0 (0) | / | ||
| 250 V/2.5 ms | 56/58 (97) | E14 | 3/24 (12.5) | 1 (33) | 0 (0) | / | |||
| 300 V/0.5 ms | 27/29 (93) | E14 | 6/29 (21) | 3 (50) | 0 (0) | / | |||
| 300 V/2.5 ms | 24/29 (83) | E14 | 1/29 (3.4) | 1 (100) | 0 (0) | / | |||
| 3/150/3 × 100 | 250 V/0.5 ms | 36/37 (97) | E14 | 9/34 (26.5) | 2 (22) | 1*(11) | E.OVL-E5.5 | ||
| 250 V/2.5 ms | 66/82 (80) | E14 | 4/66 (6.1) | 1 (25) | 1*(25) | E.OVL-E6.3 | |||
| 300 V/0.5 ms | 79/82 (96) | E14 | 16/69 (23) | 4 (25) | 2* (12.5) | E.OVL-E7.1 E.OVL-E7.7 | |||
| 300 V/2.5 ms | 31/43 (72) | E14 | 1/31 (3.23) | 1 (100) | 0 (0) | / | |||
| 3/150/3 × 200 | 300 V/0.5 ms | 109/121 (90) | E14 | 8/70 (11) | 6 (75) | 0 (0) | / | ||
| 300 V/2.5 ms | 40/55 (73) | E14 | 3/40 (7.5) | 0 (0) | 0 (0) | / | |||
| OVL 1.5p-2 antisens-3.3p | 3/150/3 × 20 | Microinjection | 52/65 (80) | E14 | 22/52 (42) | 6 (27) | 3* (14) | M.OVLas-E6 M.OVLas-E15 M.OVLas-E22 | |
| 3/150/3 × 50 | 250 V/0.5 ms | 40/42 (95) | E14 | 10/35 (29) | 3 (30) | 1* (10) | E.OVLas-E5.6 | ||
| 250 V/2.5 ms | 36/54 (67) | E14 | 0/36 (0) | / | / | / | |||
| 300 V/0.5 ms | 43/48 (90) | E14 | 0/37 (0) | / | / | / | |||
| 300 V/2.5 ms | 34/60 (57) | E14 | 0/34 (0) | / | / | / | |||
| 3/150/3 × 100 | 250 V/2.5 ms | 85/105 (81) | E14 | 0/57 (0) | / | / | / | ||
| 300 V/0.5 ms | 105/116 (91) | E14 | 8/71 (11) | 1 (12.5) | 0 (0) | / | |||
| 300 V/2.5 ms | 123/207 (59) | E14 | 1/91 (1.1) | 0 (0) | 0 (0) | / | |||
| 3/150/3 × 200 | 300 V/0.5 ms | 52/54 (96) | E14 | 10/52 (19) | 4 (40) | 0 (0) | / | ||
| 300 V/2.5 ms | 36/47 (77) | E14 | 1/36 (2.8) | 0 (0) | 0 (0) | / |
aCalculated 1 h after electroporation. bCalculated from the number of transferred eggs. cCalculated from the number of analyzed embryos or pups. dSequences of these embryos are in the Fig. 4. *partial insertion.